News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Press Releases
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
July 25, 2024
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Attachment
2024 Ipsen Half-Year Financial Report
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
GLP-1
UK’s MHRA Finds No Risk of Suicidal Ideation, Self-Harm With GLP-1 Drugs
September 5, 2024
·
2 min read
·
Tristan Manalac
Multiple sclerosis
Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
September 4, 2024
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Plots Leqvio Expansion After Lowering Cholesterol in Phase III Study
August 29, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error
August 27, 2024
·
1 min read
·
Annalee Armstrong